Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort

ABSTRACT The angiogenic factors sFlt-1 and PlGF play an established role in the detection of preeclampsia (PE). Recent data suggest that sEng might contribute to the pathogenesis of PE. However, only a few studies so far have addressed its role. This monocentric cross-sectional study of high-risk pregnancies aims to compare the levels of sFlt-1/PlGF ratio and sEng depending on different placental-related adverse pregnancy outcomes. The statistical analysis takes into account Pearson’s correlation coefficient between angiogenic factors, the area under the curve estimates (AUCs) for detection, and adjusted odds ratios (aOR) with 95% confidence intervals (95%-CIs). The analysis included 206 patients: 60 controls, 90 PE (59 EOPE, 35 LOPE), 94 FGR, and 35 HELLP cases. Some outcomes overlapped because FGR commonly complicated PE and HELLP syndrome. Serum levels of sFlt-1/PlGF and sEng correlated with each other. Higher levels were observed in HELLP syndrome and EOPE cases. AUCs for sFlt-1/PlGF ratio and sEng were, respectively, 0.915 (95%-Cl 0.87-0.96) and 0.872 (95%-Cl 0.81-0.93) in PE, 0.895 (95%-Cl 0.83-0.96) and 0.878 (95%-Cl 0.81-0.95) in HELLP syndrome, 0.891 (95%-Cl 0.84-0.94), and 0.856 (95%-Cl 0.79-0.92) in FGR.aORsfor sFlt-1/PlGF ratio and sEng were, respectively: 2.69 (95%-Cl 1.86-3.9) and 2.33 (95%-Cl 1.59-3.48) in PE, 2.38 (95%-Cl 1.64-3.44) and 2.28 (95%-Cl 1.55-3.4) in FGR, and 2.10 (95%-Cl 1.45-3.05) and 1.88 (95%-Cl 1.31-2.69) in HELLP syndrome. In addition, the aORs between sFlt-1/PlGF and sEng were very similar but higher for PE and FGR than HELLP syndrome.In conclusion,sEng performed similarly to sFlt-1/PlGF to detect placental dysfunctions.

[1]  C. Lees,et al.  ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. , 2020, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[2]  A. Leaños-Miranda,et al.  Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes. , 2019, Hypertension.

[3]  K. Nicolaides,et al.  The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[4]  S. Karumanchi,et al.  Preeclampsia: Pathophysiology, Challenges, and Perspectives , 2019 .

[5]  J. Gris,et al.  Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: AngioPred study , 2019, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[6]  L. Magee,et al.  Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. , 2018, Hypertension.

[7]  L. Magee,et al.  The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. , 2018, Pregnancy hypertension.

[8]  D. Charnock-Jones,et al.  Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. , 2017, American journal of obstetrics and gynecology.

[9]  A. Farr,et al.  An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia. , 2018, Pregnancy hypertension.

[10]  Nicola Persico,et al.  Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia , 2017, The New England journal of medicine.

[11]  E. Gratacós,et al.  An integrated approach to fetal growth restriction. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[12]  S. Brennecke,et al.  Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia , 2016, Obstetrics and gynecology.

[13]  M. Bahloul,et al.  [Up-to-date on the HELLP syndrome (Hemolysis, Elevated Liver enzymes and Low Platelets)]. , 2016, La Revue de medecine interne.

[14]  A. Papageorghiou,et al.  Consensus definition of fetal growth restriction: a Delphi procedure , 2016, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[15]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[16]  K. Nicolaides,et al.  Longitudinal changes in maternal soluble endoglin and angiopoietin‐2 in women at risk for pre‐eclampsia , 2014, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[17]  K. Gomes,et al.  Soluble Endoglin, Transforming Growth Factor-Beta 1 and Soluble Tumor Necrosis Factor Alpha Receptors in Different Clinical Manifestations of Preeclampsia , 2014, PloS one.

[18]  H. Zeisler,et al.  New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia , 2014, Hypertension.

[19]  O. Shaker,et al.  Pathogenesis of preeclampsia , 2013, Human & experimental toxicology.

[20]  K. Nicolaides,et al.  Maternal Serum Soluble Endoglin at 30-33 Weeks in the Prediction of Preeclampsia , 2012, Fetal Diagnosis and Therapy.

[21]  K. Lim,et al.  Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia , 2012, PloS one.

[22]  Kypros H. Nicolaides,et al.  Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers , 2012, Fetal Diagnosis and Therapy.

[23]  J. Oleszczuk,et al.  Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[24]  K. Lim,et al.  Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia , 2012, Circulation.

[25]  L. Cordero,et al.  Maternal Preeclampsia and Neonatal Outcomes , 2011, Journal of pregnancy.

[26]  J. Dudenhausen,et al.  An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. , 2010, American journal of obstetrics and gynecology.

[27]  Wenjiang J. Fu,et al.  A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[28]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[29]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[30]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[31]  J. López-Novoa,et al.  Endoglin regulates nitric oxide‐dependent vasodilatation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[33]  M. Letarte,et al.  Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. , 1990, The Journal of biological chemistry.

[34]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.